Media

Announcement

AI Proteins Announces James Bowman as Company's First Chief Technology Officer

August 26, 2025

Announcement

AI Proteins Appoints Philip E. Brandish, PhD as Chief Development Officer

February 12, 2025

Announcement

AI Proteins Enters into Collaborative Research Agreement with the University of Missouri on Radioligand Therapy

January 8, 2025

Announcement

AI Proteins Appoints Founder Dr. Chris Bahl as Chief Executive Officer; Company to Present at Biotech Showcase 2025 during J.P. Morgan Healthcare Week

January 7, 2025

Announcement

AI Proteins Announces Research Collaboration and Option Agreement with Bristol Myers Squibb for Miniprotein-Based Therapeutics Valued up to $400M

December 3, 2024

Announcement

AI Proteins Selected as a Winner of the Falling Walls Venture Science Start-up Competition

November 6, 2024

Announcement

AI Proteins to Attend BIO 2024; Company Provides Update on Technology Platform and Programs

May 30, 2024

Announcement

Vivtex and AI Proteins Enter Strategic R&D Collaboration to Develop Novel, Oral Biologic Therapies

January 18, 2024

Announcement

AI Proteins Announces the Appointment of Dr. Robert Stein to its Scientific Advisory Board

October 4, 2023

Announcement

AI Proteins Announces the Formation of a Scientific Advisory Board Made up of Experts in Biotech and FDA Drug Approval

May 31, 2023

Announcement

AI Proteins Expands Executive Team with Hire of Wendy Dwyer as Chief Business Officer

December 14, 2022

Announcement

AI Proteins Secures $18.2 Million Seed Round to Pioneer High-throughput Platform for Advanced Miniprotein Therapeutics

November 3, 2022